ClinicalTrials.gg
CompletedNCT00778271Updated Oct 23, 2008

Bioequivalence Study of Gabapentin 400 mg Capsules Under Fasting Conditions

An interventional study of Gabapentin 400mg capsules in Healthy, sponsored by Ranbaxy Laboratories Limited. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-10-23.

Sponsored by Ranbaxy Laboratories Limited (part of Sun Pharmaceutical Industries Limited) · Not applicable and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Parke-Davis (Neurontin®) 400 mg Gabapentin, following administration of a 400 mg dose under fasting conditions

Read the detailed description

This was an open-label, randomized, single-dose, 2-way crossover relative bioavailability study performed on 24 healthy adult volunteers and 2 alternates. A total of 26 subjects (22 males and 4 females) completed the clinical phase of the study. In each period, subjects were housed from at least 10 hours before dosing until after the 36-hour blood draw. Both periods were separated by a wash out period of 7 days A total of 26 healthy adult volunteers (22 males and 4 non-pregnant females) enrolled in and completed the clinical phase of the study enrolled in and completed the clinical phase of the study

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence gabapentin 400mg capsules fasting conditions
03

In context

Lead sponsor

Ranbaxy Laboratories Limited is the lead sponsor of 100 studies on the registry; none are open to participants now.

First submitted before Ranbaxy Laboratories Limited became part of Sun Pharmaceutical Industries Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female volunteers, 18-55 years of age
  2. Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983)
  3. Medically healthy subjects with clinically normal laboratory profiles
  4. Females of should either be sexually inactive (abstinent) for 14 days prior to the study and throughout the study or be using one of the following acceptable methods:

    • surgically sterile (bilateral tubal ligation, hysterectomy bilateral oophorectomy) 6 months minimum;
    • IUD in place for at least 3 months;
    • barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the start of the study and throughout the study;
    • surgical sterilization of the partner (vasectomy for 6 months minimum); OR
    • hormonal contraceptives for at least 3 months prior to the start of the study.

    Other birth control methods may be deemed acceptable. women with amenorrhea for at least 2 years will be eligible.

  5. Voluntarily consent to participate in the study

Exclusion criteria

Exclusion Criteria:

Subject candidates must not be enrolled in the study if they meet any of the following criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  2. In addition, history or presence of:

    • alcoholism or drug abuse within the past 2 years; OR
    • or idiosyncratic reaction to antibiotics, especially penicillins, cephalosporins and amoxicillin and/or clavulanic acid.
  3. Female subjects who are pregnant or lactating
  4. Subjects who have been on an abnormal diet (for whatever reason) during the 30 days prior to the first dose
  5. Subjects who, through completion of the study, would have donated in excess of:

    • 500 mL of blood in 14 days, or
    • 500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator),
    • 1000 mL of blood in 90 days
    • 1250 mL of blood in 120 days
    • 1500 mL of blood in 180 days
    • 2000 mL of blood in 270 days
    • 2500 mL of blood in I year f) Subjects who have participated in another clinical trial within 28 days prior to the first dose
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    Gabapentin 400mg capsules

    Drug: Gabapentin 400mg capsules

  • Active comparator
    2

    Neurontin® 400 mg capsules

    Drug: Gabapentin 400mg capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence

07

Study locations

1 site
  • MDS Pharma Services
    Saint-Laurent,, Quebec, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of Oct 2002 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2008
First posted
Oct 23, 2008
Start
Sep 2002
Primary completionActual
Oct 2002
CompletionActual
Dec 2002
Last update
Oct 23, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00778271
First posted
Oct 23, 2008
Start date
Sep 2002
Primary completion
Oct 2002
Completion
Dec 2002
Last update
Oct 23, 2008

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion